e-learning
resources
Paris 2018
Monday, 17.09.2018
CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Antioxidant and anti-inflammation effect of GHK-Cu in bleomycin-induced pulmonary fibrosis
G. Hou (Shenyang, China), X. Zhou (Shenyang, China)
Source:
International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Session:
CTD-ILD and hypersensitivity pneumonitis: mechanistic insights and prognostic markers
Session type:
Thematic Poster
Number:
2957
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
G. Hou (Shenyang, China), X. Zhou (Shenyang, China). Antioxidant and anti-inflammation effect of GHK-Cu in bleomycin-induced pulmonary fibrosis. 2957
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: Diagnostic tools for Obstructive Sleep Apnoea in adults and children
Expert interview: Physiological classification of lung function impairment
Occupational exposures to respiratory diseases: A case-based discussion
Related content which might interest you:
Anti-inflammatory and anti-fibrotic effects of sirolimus in bleomycin-induced pulmonary fibrosis in rats
Source: Annual Congress 2010 - Experimental approaches in pulmonary fibrosis
Year: 2010
The effect of curcumin on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 827s
Year: 2006
Comparison of in-vivo anti-fibrotic effects of pirfenidone and nintedanib in bleomycin-induced pulmonary fibrosis model
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Time course of bleomycin-induced pulmonary fibrosis and the antifibrotic effect of losartan
Source: Annual Congress 2007 - Mechanisms of injury and repair in fibrotic, idiopathic or infectious lung disease
Year: 2007
Therapeutic effect of combination of salvia and ligustrazine on bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2011 - What is new in the approach to pulmonary fibrosis?
Year: 2011
Anti-fibrotic effect of telmisartan on bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies
Year: 2008
Antifibrotic effects of Lck inhibition on bleomycin-induced pulmonary fibrosis in mice
Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2019
Estimation of antibiotic effect on the development of bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Miscellaneous aspects of interstitial lung disease
Year: 2008
HSP47siRNA targeting to myofibroblasts attenuates bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2012 - Interstitial lung disease: from bench to bedside
Year: 2012
Effects of aerosolized earthworm fibrinolytic enzyme on bleomycin-induced pulmonary fibrosis in rats
Source: Eur Respir J 2006; 28: Suppl. 50, 766s
Year: 2006
Effect of curcumin on inflammation in experimental pulmonary fibrosis
Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation
Year: 2007
Inhibitory effects of somatostatin analogue in bleomycin-induced pulmonary fibrosis
Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology?
Year: 2008
The effect of interferon-γ on bleomycin-induced alveolitis and pulmonary fibrosis in rats
Source: Eur Respir J 2005; 26: Suppl. 49, 81s
Year: 2005
Effect of fasudil on the bleomycin-induced pulmonary fibrosis and hypertension in mice
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Year: 2012
PBI-compound, a novel first-in-class anti-inflammatory/fibrotic compound, reduces bleomycin-induced pulmonary fibrosis by inhibition of multiple pro-inflammatory/fibrotic key mediators
Source: Annual Congress 2013 –Cell signalling and inflammation: what's new in 2013?
Year: 2013
Fibroblasts positive for meflin have anti-fibrotic properties in pulmonary fibrosis
Source: Eur Respir J, 58 (6) 2003397; 10.1183/13993003.03397-2020
Year: 2021
Effects of NecroX compounds on bleomycin-induced pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
17(R)-resolvin D1 attenuates bleomycin-induced lung fibrosis in mice
Source: Annual Congress 2013 –Novel in vitro and animal models to study lung diseases
Year: 2013
Anti-fibrotic efficacy of nintedanib on pulmonary fibrosis via suppression of fibrocyte activity
Source: International Congress 2016 – IPF: from pathogenesis to treatment I
Year: 2016
Danshenextract salt Inhibits bleomycin-induced experimental pulmonary fibrosis
Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis
Year: 2020
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept